Saniona Icon blue


Precise modulation of ion channels for inflammation and fibrosis

SAN903 is a potential first-in-class inhibitor of the calcium-activated potassium ion channel, KCa3.1. It has passed preclinical development for the treatment of inflammatory and fibrotic disorders. Current lead indication is inflammatory bowel diseases (IBD).

How SAN903 works



Tesomet Infographics

NO cytokine/collagen production

NO cell division and migration

The calcium-activated potassium channel, KCa3.1, is important for activation of immune cells in the brain and other tissues, and it is also involved in the abnormal production of connective tissue that can lead to fibrosis in chronic diseases. Saniona has leveraged its ion channel drug discovery engine to precisely target KCa3.1. SAN903 has shown efficacy in preclinical models for inflammation and fibrosis without side effects.


Saniona’s anti-inflammatory and anti-fibrotic candidate SAN903 is ready for clinical studies.